Artificial Intelligence, Retina/Vitreous
Read Time: 10 mins

Artificial Intelligence for the Diagnosis and Screening of Retinal Diseases

Copy Link
Published Online: Jul 21st 2023 touchREVIEWS in Ophthalmology. 2023;17(2):9-14 DOI:
Authors: Alessandro Arrigo, Emanuela Aragona, Francesco Bandello
Quick Links:
Article Information

Artificial intelligence (AI) is becoming established as a new method for analysing ophthalmological data, and unveiling new clinical and pathogenic insights into retinal diseases. AI-based algorithms are largely employed in the field of the most prevalent retinal diseases, including diabetic retinopathy, age-related macular degeneration and myopia. Several research groups are also testing AI in other retinal diseases, including inherited retinal dystrophies, retinopathy of prematurity, central serous chorioretinopathy and retinal vein occlusion. AI models are mainly used in screening of the fundus and structural optical coherence tomography images. However, more advanced methodologies are under investigation to extract clinically relevant information regarding the biomarkers of disease activity and outcome measures. AI is a powerful tool for increasing the amount of information obtained in clinical and research contexts. However, many issues still need addressing, including the resulting high demand for technology and resources, and the need for very large databases. Moreover, several ethical issues require debate, and specific rules are needed to govern the use of AI algorithms and check the quality of the analysed data. This article reviews the current use of AI in retinal diseases, unmet needs and future perspectives.


Age-related macular degenerationdiabetic retinopathyscreeningdiagnosisartificial intelligence.


Article highlights

  • Artificial intelligence (AI) represents a powerful way of analysing a large amount of data, extracting those features characterizing a given disease or condition.

  • AI-based models have been largely tested in the main retinopathies, including age-related macular degeneration, diabetic retinopathy and myopia.

  • AI algorithms have been highly effective in screening for retinopathies.

  • The same approaches have unveiled potentially relevant biomarkers of disease progression and complications.

  • Future efforts should focus on developing data quality checks and validating methodologies to reliably assess the contribution of AI-based models in clinical and research settings.

Background: Artificial intelligence and its application in ophthalmology

The term ‘artificial intelligence’ first appeared in 1956.1 One of the most frequently used definitions comes from a paper by Kaplan and Haenlein, who defined AI systems as having “the ability to process external data systematically and learn from it to achieve specific goals and tasks”.2

The rapid growth of AI-based approaches in several disciplines stimulated the application of this technology in medicine. AI includes different possible approaches, which are usually categorized according to the method used to present a given problem to the machine. In particular, we can distinguish machine learning (ML) and deep learning (DL) technologies.

ML is defined as “computers’ ability to learn without being explicitly programmed”.3 In brief, ML uses raw data to extract learning information to train the algorithm and build models. There are different approaches in ML, the descriptions of which are beyond the scope of this review. Overall, ML approaches can be supervised or unsupervised, depending on the presence of human supervision.3

DL is an evolution based on a more complex extraction and analysis of data. Indeed, DL involves the use of deep neural networks, a complex multi-layer organization that is able to extract and elaborate complex patterns in data and to perform much more advanced and reliable analyses.4–6 The main differences between ML and DL are as follows:

  • Data requirements: DL requires more data than ML to train the model on the basis of much more complex patterns.

  • Extraction of the features: ML models usually manually extract the features from the data to train the model, whereas DL algorithms are able to automatically learn the features from the data.

  • DL requires higher computational power and costs more than ML.

  • Interpretation: ML models are usually easier to interpret than DL models.

The main AI models are graphically summarized in Figure 1. A schematic of the main differences between ML and DL is shown in Figure 2.

Both ML and DL base data processing on artificial neural networks. That is, an imitation of the neural structure of the central nervous system. The information is then divided into different layers to facilitate data elaboration and the processing of inputs to outputs.

Considering all these characteristics, ophthalmology is well suited to the requirements of AI model development. Indeed, thanks to current diagnostic approaches, ophthalmologists can acquire very large datasets that are highly reliable, high quality and non-invasive way. This is particularly true in the medical retina field, where non-invasive multi-modal retinal imaging represents the cornerstone of retinal diagnostics.7

In this article, we provide an updated overview of AI application for the most common retinal diseases.


We searched all English language and human subject articles using a keyword search of the MEDLINE library. Keywords included the following: artificial intelligence, machine learning, deep learning, macular disease, retinal disease, retinopathy and maculopathy. All the references were carefully examined by two expert researchers (FB, AA), who collected and ordered all the relevant information according to the main topic of the review.

Artificial intelligence models in diabetic retinopathy

Diabetic retinopathy (DR) represents a major cause of visual impairment in developed countries. The ever-growing incidence of DR and its complications necessitates new strategies to screen patients, prevent complications and optimize management. For this reason, DR is a major target of AI-based models, especially those that can be used for large-scale screening. AI models should recognize DR-related alterations, such as haemorrhages, exudates, cotton wool spots and neovascularization; and, starting from fundus images, establish the presence or absence of DR, and grade it according to the conventional DR grading scales.

Several AI systems have been developed to reach this goal. The IDx-DR system (Digital Diagnostics, Coralville, IA, USA) combines the results from DR-related biomarkers to grade DR. It was included in the Iowa Detection Program and tested in Caucasian, North African and sub-Saharan populations. This included images from 3,640 participants in the Nakuru Eye Study in Kenya, and reached a sensitivity of 87% and a specificity of 70%.8 The IDx-DR system was also tested in the Messidor-2 dataset (ADCIS, Saint-Contest, France) – which was established to facilitate the testing of computer-assisted diagnosis of DR – including fundus images of 1,748 eyes (874 patients), with a sensitivity of 97% and a specificity of 59%.9,10 Similar results have have also been achieved in real-life settings.11 Thanks to these good results, IDx-DR obtained approval from the United States Food and Drug Administration in 2018.12 The device can also work in conjunction with the Topcon NW400 non-mydriatic fundus camera (Topcon Healthcare, Tokyo, Japan).13

The RetmarkerDR software (Critical Health SA, Coimbra, Portugal) is a Conformité Européene-marked class IIa medical device capable of distinguishing DR from non-DR eyes and measuring the microaneurysm turnover rate during follow-up.14,15 The system had a sensitivity of 73% for any DR, 85% for referable DR and 98% for proliferative DR.16 A similar system is EyeArt (Eyenuk Inc., Woodland Hills, CA, USA), which has a sensitivity of 95% for any DR, 94% for referable DR and 99.6% for proliferative DR.16 EyeArt was also tested on the Messidor-2 dataset, reaching a sensitivity of 94% and a specificity of 72%.17 EyeArt was implemented in smartphone-based DR screening of 296 patients, with a sensitivity of 96% for any DR, 99% for referable DR and 99% for sight-threatening DR.18 More recently, this tool has been employed on a dataset of more than 30,000 images, with a sensitivity of 96% for referable DR.19

Other systems with similar sensitivities and specificities are a Google Inc. sponsored system (Mountain View, CA, USA),20 Bosch DR Algorithm (Robert Bosch, GmbH, Gerlingen, Germany),21 a system developed by the Singapore National Eye Centre, Singapore Eye Research Institute and National University of Singapore School of Computing,22 RetinaLyze (Retinalyze A/S, Hørsholm, Denmark)23–25 and EyeWisdom® (Visionary Intelligence Ltd [Vistel], Beijing, China).26 Further AI-based DR screening systems are listed in the recent review by Grzybowski et al.27 The high reliability of AI-based screening has been further supported by a recent study testing a DL algorithm to analyse 14 common retinal alterations by using more than 200,000 fundus images derived from 16 clinical settings with different disease distributions.28

Another application of AI in the DR setting is in the grading and staging of the disease. Indeed, it is assumed that AI models may help ophthalmologists to optimize the detection and analysis of DR-related alterations, thus optimizing DR diagnostic work-up. Gulshan et al. tested AI for this purpose in 2016, achieving very high sensitivity and specificity in categorizing DR severity and the presence of diabetic macular oedema.20 Ting et al. supported these findings in 2017 by analysing almost half a million images.22

Artificial intelligence models in age-related macular degeneration

Age-related macular degeneration (AMD) represents another leading cause of visual impairment in developed countries and a major target for AI-based approaches. The analysis of AMD data is mainly based on optical coherence tomography (OCT) images; thus, image segmentation is a fundamental step for accurately recognizing retinal structures. Many unsupervised AI-based segmentation algorithms have been developed, providing very high performance in detecting retinal features.29–33 These algorithms are useful not only for assessing the integrity of retinal structures, but also for localizing and quantifying retinal fluids during follow-up. Many approaches have been proposed in recent years, providing comparable results in terms of reliability, and these have been excellently reviewed by Schmidt-Erfurth et al.34

Interestingly, AI has facilitated further progress in the AMD field, helping to assess treatment responses and factors predicting visual outcome. Moraes et al. used AI to assess distinctive features in first- and second-treated AMD eyes, highlighting differences in terms of AMD-related lesion prevalence and the course of the disease.35 Similarly, AI has proved useful in quantifying drusen and assessing their topographic distribution, both in fundus and OCT images, as well as for analysing hyper-reflective foci on OCT scans in early to intermediate AMD stages. These factors were used to calculate the risk of disease progression and onset of complications.36–38 In this context, Schmidt-Erfurth et al. provided important contributions regarding the use of AI in AMD:

  • predicting the risk of AMD progression;39

  • highlighting the prognostic importance of intra-retinal cystoid fluid in neovascular AMD;40

  • developing automatic approaches for calculating fluid volumes to improve therapeutic management of neovascular AMD;41

  • assessing the efficacy profiles of two different anti-vascular endothelial growth factor drugs.42

More recently, AI has successfully predicted visual outcomes for a treat-and-extend regimen, by using the changes in intra-retinal and sub-retinal fluids after single injections as predictive factors.43 AI-based approaches were useful for segmenting images of macular neovascularizations and for quantifying leakage on fluorescein angiography.44 However, although fluid changes have been investigated as important predictive biomarkers in neovascular AMD, a recent AI-based study found no significant relationship between OCT angiography characteristics of the macular neovascularizations and the response to treatments.45

Moving beyond neovascular complications, AI has also been employed in the setting of geographic atrophy, based on the high reliability of AI-based algorithms to detect atrophic margins and to follow the expansion over time.46–51 Recently, AI has been tested alongside a novel treatment for geographic atrophy, namely pegcetacoplan. AI-based models were useful in calculating the topography and progression rate of geographic atrophy,52 as well as in quantifying photoreceptor thinning and loss over time.53

A very interesting application of AI-based technology is in self-monitoring of macular status. One such system is the Notal Vision Home OCT (Notal Vision, Manassas, VA, USA). In a recent study, patients performed daily self-imaging at home using this system for 3 months, with the aim of daily monitoring neovascular activity by OCT images and AI-based elaboration. This system turned out to be feasible and fast, showing very good agreement with expert-based grading of disease activity.54 A similar self-monitoring strategy was tested in dry AMD with the ForeseeHome system (Notal Vision). This device collected clinical data from 2,123 patients over a mean duration of 3 years, and was highly feasible and useful in detecting changes in visual acuity and producing alert signals regarding the risk of disease progression.55

Artificial intelligence models in myopia

Myopia is a global epidemic that is predicted to affect almost 50% of the world’s population by 2050.56 High myopia, defined as a spherical equivalent of 5.00 D or more, is a common finding, leading to potentially vision-threatening complications, such as myopic maculopathy and retinal detachment. Therefore, the development of even more powerful diagnostic approaches is fundamental to guaranteeing optimal management of myopic complications, and AI can play a major role in this field. Several AI algorithms have been tested to detect signs of pathological myopia both in fundus and OCT images.57–63 All these algorithms showed high reliability and sensitivity in detecting myopic alterations, with area under the curve values in most cases being ≥0.9.

The ability of AI-based models to improve the detection of pathological myopia paves the way for earlier diagnosis of myopic complications, and better management.64 Similarly, AI has been employed for the prediction of myopia progression and calculation of the risk of developing high or even pathological myopia.65–67 The use of AI-based models in myopia has gone beyond the retinal field, with applications also in refractive and cataract surgeries to improve pre-surgical calculations and refractive outcomes.68–71

New frontiers for the use of artificial intelligence models in retinal diseases

Although DR, AMD and myopia undoubtedly represent major diseases of interest for AI-based models, the potential for more extensive employment of AI methods in other retinal diseases is now also more likely. This includes other common retinal diseases, such as retinal vein occlusion, central serous chorioretinopathy and vitreoretinal disorders.72–79

AI has been tested in inherited retinal dystrophies to segment retinal structures on OCT, to detect atrophic changes and to follow all these alterations over time. In particular, AI models have been used in retinitis pigmentosa,80–82 choroideremia80,83 and Stargardt disease.81,84–86 The intriguing goal in this field is to improve characterization of patients with inherited retinal dystrophies and to study the genotype–phenotype correlations in very large cohorts of patients.

Another field of interest for AI models is retinopathy of prematurity (ROP), which is a major ophthalmological problem worldwide and a diagnostic clinical challenge.87 Many AI-based algorithms have been tested to screen for ROP and/or monitor disease progression.88–93 The diagnostic improvement of ROP provided by AI models could allow earlier identification and prompt treatment, which would reduce the impact on visual function and improve patients’ quality of life. Recently, a large study validated a vascular severity score as an appropriate output for AI-based models, finding a good correlation with the International Classification of Retinopathy of Prematurity staging system and paving the way for expanded use of AI algorithms in diagnosing ROP.94 Although the data available in the current literature should not be considered conclusive, more extensive use of AI-based approaches in both clinical practice and research is likely.

Current limitations of artificial intelligence models: The other side of the medal

Although the contribution of AI-based algorithms is clear to the entire scientific community, the extensive use of AI technology is affected by several issues. First, the clinical validation of AI findings is mandatory to definitively assess the use of AI models in ophthalmology. Indeed, up to now, no standardized methods for evaluating the accuracy and robustness of AI methodology and findings have been developed. This limitation means that AI technologies are currently only used in research.

Major AI-related issues concern the usability, accessibility and cost demands of AI technologies. Indeed, AI models are expensive and require advanced technical skills and computational power, which strongly limits their use in areas with limited resources. In addition, AI algorithms require big data, which are difficult to collect in clinical practice. The feasibility of collecting data in daily practice, and the potential for patient distress in obtaining the data, should be carefully considered. The requirement for large amounts of data also leads irremediably to high heterogeneity in data quality. Indeed, we may assume that not all the data included in AI models are characterized by the same level of quality. For this reason, new ways of checking and classifying data quality are mandatory to improve the accuracy and relevance of the output from AI models.

Another major pitfall relates to data privacy and cybersecurity, given that AI technologies are often connected to the web. In addition, AI models are strongly associated with telemedicine strategies, with the potential for ethical biases, which should be carefully addressed. Although telemedicine has the undoubted advantage of increasing access to diagnostic procedures and reducing the burden for hospitals, it is impersonal and could significantly undermine the doctor–patient relationship and the inter-human emphatic exchanges that are the basis of care.95 Moreover, automating data analysis and interpretation provided by AI models is not synonymous with competence. AI technologies do not have the necessary expertise, intuition or critical thinking that are fundamental to properly interpreting findings and to reaching a diagnosis and considering therapeutic solutions. Therefore, human input will always be needed to process the output of AI technologies.


The current article provides an up-to-date review of AI-based technologies in retinopathies. AI has huge potential to improve the diagnostic work-up and management of retinopathies. Moreover, some studies have shown promising results in using AI-based approaches for the daily self-monitoring of patients. Currently, AI algorithms are mainly confined to research settings, especially in screening for the main retinopathies and identifying possible biomarkers of progression. However, the rapid growth of AI-based models is likely to result in wider adoption of these approaches both in clinical and research settings in the future. Caution is advised as power without control is potentially dangerous and many unmet needs remain. Novel methods for checking data quality and for validation are warranted to guarantee appropriate and responsible employment of AI technology in ophthalmology and healthcare systems.

Article Information:

Francesco Bandello is consultant for: Alcon, Alimera Sciences, Allergan Inc., Farmila-Thea, Bayer Schering Pharma, Bausch + Lomb, Genentech, Hoffmann-La Roche, Novagali Pharma, Novartis, Sanofi-Aventis, Thrombogenics, Zeiss. Alessandro Arrigo and Emanuela Aragona have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Alessandro ArrigoIRCCS San Raffaele Scientific InstituteVita-Salute San Raffaele University, via Olgettina 60Milan, Italy;


No funding was received in the publication of this article.


This article is freely accessible at ©Touch Medical Media 2023.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




1. Puppe FIntroduction to knowledge systemsArtif Intell Med1997;9:2013DOI10.1016/S0933-3657(96)00372-7.

2. Kaplan AHaenlein MSiri, Siri, in my hand: Who’s the fairest in the land? On the interpretations, illustrations, and implications of artificial intelligenceBus Horiz2019;62:1525DOI10.1016/j.bushor.2018.08.004.

3. Samuel ALSome studies in machine learning using the game of checkersIBM J Res & Dev1959;3:21029DOI10.1147/rd.33.0210.

4. Chauhan NKSingh KA review on conventional machine learning vs deep learning2018 International Conference on Computing, Power and Communication Technologies (GUCON)2018Greater Noida, Uttar Pradesh, India DOI10.1109/GUCON.2018.8675097.

5. Choi RYCoyner ASKalpathy-Cramer Jet alIntroduction to machine learning, neural networks, and deep learningTransl Vis Sci Technol2020;9:14DOI10.1167/tvst.9.2.14.

6. Kumar KKumar PDeb Det alArtificial intelligence and machine learning based intervention in medical infrastructure: A review and future trendsHealthcare (Basel)2023;11:207DOI10.3390/healthcare11020207.

7. Arrigo AAragona EBattaglia Parodi MBandello FQuantitative approaches in multimodal fundus imaging: State of the art and future perspectivesProg Retin Eye Res2023;92:101111DOI10.1016/j.preteyeres.2022.101111.

8. Hansen MBAbràmoff MDFolk JCet alResults of automated retinal image analysis for detection of diabetic retinopathy from the Nakuru study, KenyaPLoS One2015;10:e0139148DOI10.1371/journal.pone.0139148.

9. Abràmoff MDFolk JCHan DPet alAutomated analysis of retinal images for detection of referable diabetic retinopathyJAMA Ophthalmol2013;131:3517DOI10.1001/jamaophthalmol.2013.1743.

10. ACDIS. MessidorAvailable at (Date last accessed9 June 2023).

11. van der Heijden AAAbramoff MDVerbraak Fet alValidation of automated screening for referable diabetic retinopathy with the Idx‐DR device in the Hoorn diabetes care systemActa Ophthalmol2018;96:638DOI10.1111/aos.13613.

12. US Food & Drug AdministrationFDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. news release, April 2018DOI10.31525/fda2-ucm604357.htm.

13. Abràmoff MDLavin PTBirch Met alPivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care officesNPJ Digit Med2018;1:39DOI10.1038/s41746-018-0040-6.

14. Ribeiro LOliveira CMNeves Cet alScreening for diabetic retinopathy in the central region of Portugal. Added value of automated ‘disease/no disease’ gradingOphthalmologica2015;233:96103DOI10.1159/000368426.

15. Ribeiro MLNunes SGCunha-Vaz JGMicroaneurysm turnover at the macula predicts risk of development of clinically significant macular edema in persons with mild nonproliferative diabetic retinopathyDiabetes Care2013;36:12549DOI10.2337/dc12-1491.

16. Tufail AKapetanakis VVSalas-Vega Set alAn observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectivenessHealth Technol Assess2016;20:172DOI10.3310/hta20920.

17. Solanki KRamachandra CBhat Set alEyeart: Automated, high-throughput, image analysis for diabetic retinopathy screeningInvest Ophthalmol Vis Sci2015;56:1429.

18. Rajalakshmi RSubashini RAnjana RMMohan VAutomated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligenceEye2018;32:113844DOI10.1038/s41433-018-0064-9.

19. Heydon PEgan CBolter Let alProspective evaluation of an artificial intelligence-enabled algorithm for automated diabetic retinopathy screening of 30 000 patientsBr J Ophthalmol2021;105:7238DOI10.1136/bjophthalmol-2020-316594.

20. Gulshan VPeng LCoram Met alDevelopment and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographsJAMA2016;316:240210DOI10.1001/jama.2016.17216.

21. Bawankar PShanbhag NSmitha SKet alSensitivity and specificity of automated analysis of single-field non-mydriatic fundus photographs by Bosch DR Algorithm—Comparison with mydriatic fundus photography (ETDRS) for screening in undiagnosed diabetic retinopathyPLoS One2017;12:e0189854DOI10.1371/journal.pone.0189854.

22. Ting DSWCheung CY-LLim Get alDevelopment and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetesJAMA2017;318:221123DOI10.1001/jama.2017.18152.

23. Larsen NGodt JGrunkin Met alAutomated detection of diabetic retinopathy in a fundus photographic screening populationInvest Ophthalmol Vis Sci2003;44:76771DOI10.1167/iovs.02-0417.

24. Hansen ABHartvig NVJensen MSet alDiabetic retinopathy screening using digital non‐mydriatic fundus photography and automated image analysisActa Ophthalmol Scand2004;82:66672DOI10.1111/j.1600-0420.2004.00350.x.

25. Larsen MGodt JLarsen Net alAutomated detection of fundus photographic red lesions in diabetic retinopathyInvest Ophthalmol Vis Sci2003;44:7616DOI10.1167/iovs.02-0418.

26. Pei XYao XYang Yet alEfficacy of artificial intelligence-based screening for diabetic retinopathy in type 2 diabetes mellitus patientsDiabetes Res Clin Pract2022;184:109190DOI10.1016/j.diabres.2022.109190.

27. Grzybowski ABrona PLim Get alArtificial intelligence for diabetic retinopathy screening: A reviewEye (Lond)2020;34:45160DOI10.1038/s41433-019-0566-0.

28. Lin DXiong JLiu Cet alApplication of comprehensive artificial intelligence retinal expert (CARE) system: A national real-world evidence studyLancet Digit Health2021;3:e48695DOI10.1016/S2589-7500(21)00086-8.

29. Lee CSBaughman DMLee AYDeep learning is effective for the classification of OCT images of normal versus age-related macular degenerationOphthalmol Retina2017;1:3227DOI10.1016/j.oret.2016.12.009.

30. Lee CSTyring AJDeruyter NPet alDeep-learning based, automated segmentation of macular edema in optical coherence tomographyBiomed Opt Express2017;8:34408DOI10.1364/BOE.8.003440.

31. Kermany DSGoldbaum MCai Wet alIdentifying medical diagnoses and treatable diseases by image-based deep learningCell2018;172:112231DOI10.1016/j.cell.2018.02.010.

32. Vidal PLde Moura JNovo Jet alIntraretinal fluid identification via enhanced maps using optical coherence tomography imagesBiomed Opt Express2018;9:473054DOI10.1364/BOE.9.004730.

33. Schlegl TWaldstein SMBogunovic Het alFully automated detection and quantification of macular fluid in OCT using deep learningOphthalmology2018;125:54958DOI10.1016/j.ophtha.2017.10.031.

34. Schmidt-Erfurth UReiter GSRiedl Set alAI-based monitoring of retinal fluid in disease activity and under therapyProg Retin Eye Res2022;86:100972DOI10.1016/j.preteyeres.2021.100972.

35. Moraes GFu DJWilson Met alQuantitative analysis of OCT for neovascular age-related macular degeneration using deep learningOphthalmology2021;128:693705DOI10.1016/j.ophtha.2020.09.025.

36. Waldstein SMVogl W-DBogunovic Het alCharacterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomographyJAMA Ophthalmol2020;138:7407DOI10.1001/jamaophthalmol.2020.1376.

37. Bhuiyan AWong TYTing DSWet alArtificial intelligence to stratify severity of age-related macular degeneration (AMD) and predict risk of progression to late AMDTransl Vis Sci Technol2020;9:25DOI10.1167/tvst.9.2.25.

38. Bogunovic HMontuoro ABaratsits Met alMachine learning of the progression of intermediate age-related macular degeneration based on OCT imagingInvest Ophthalmol Vis Sci2017;58:BIO14150DOI10.1167/iovs.17-21789.

39. Schmidt-Erfurth UWaldstein SMKlimscha Set alPrediction of individual disease conversion in early AMD using artificial intelligenceInvest Ophthalmol Vis Sci2018;59:3199208DOI10.1167/iovs.18-24106.

40. Schmidt-Erfurth UBogunovic HSadeghipour Aet alMachine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degenerationOphthalmol Retina2018;2:2430DOI10.1016/j.oret.2017.03.015.

41. Schmidt-Erfurth UVogl WDJampol LMBogunović HApplication of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degenerationOphthalmology2020;127:12119DOI10.1016/j.ophtha.2020.03.010.

42. Schmidt-Erfurth UMulyukov ZGerendas BSet alTherapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysisEye (Lond)2023;37:11609DOI10.1038/s41433-022-02077-4.

43. Bogunović HMares VReiter GSSchmidt-Erfurth UPredicting treat-and-extend outcomes and treatment intervals in neovascular age-related macular degeneration from retinal optical coherence tomography using artificial intelligenceFront Med (Lausanne)2022;9:958469DOI10.3389/fmed.2022.958469.

44. Holomcik DSeeböck PGerendas BSet alSegmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learningEye (Lond)2023;37:143944DOI10.1038/s41433-022-02156-6.

45. Schranz MTold RHacker Vet alCorrelation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learningActa Ophthalmol2023;101:e95105DOI10.1111/aos.15219.

46. Xu RNiu SChen Qet alAutomated geographic atrophy segmentation for SD-OCT images based on two-stage learning modelComput Biol Med2019;105:10211DOI10.1016/j.compbiomed.2018.12.013.

47. Arslan JSamarasinghe GBenke KKet alArtificial intelligence algorithms for analysis of geographic atrophy: A review and evaluationTransl Vis Sci Technol2020;9:57DOI10.1167/tvst.9.2.57.

48. Schmidt-Erfurth UBogunovic HGrechenig Cet alRole of deep learning-quantified hyperreflective foci for the prediction of geographic atrophy progressionAm J Ophthalmol2020;216:25770DOI10.1016/j.ajo.2020.03.042.

49. Arslan JBenke KKProgression of geographic atrophy: Epistemic uncertainties affecting mathematical models and machine learningTransl Vis Sci Technol2021;10:3DOI10.1167/tvst.10.13.3.

50. Zhang GFu DJLiefers Bet alClinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: A model development and external validation studyLancet Digit Health2021;3:e66575DOI10.1016/S2589-7500(21)00134-5.

51. Balaskas KGlinton SKeenan TDLet alPrediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learningSci Rep2022;12:15565DOI10.1038/s41598-022-19413-z.

52. Vogl W-DRiedl SMai Jet alPredicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learningOphthalmology Retina2023;7:413DOI10.1016/j.oret.2022.08.003.

53. Riedl SVogl W-DMai Jet alThe effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by artificial intelligence-based OCT analysisOphthalmol Retina2022;6:100918DOI10.1016/j.oret.2022.05.030.

54. Liu YHolekamp NMHeier JSLongitudinal study: Daily self-imaging with home OCT for neovascular age-related macular degenerationOphthalmol Retina2022;6:57585DOI10.1016/j.oret.2022.02.011.

55. Mathai MReddy SElman MJet alAnalysis of the long-term visual outcomes of ForeseeHome remote telemonitoring: The ALOFT studyOphthalmol Retina2022;6:9229DOI10.1016/j.oret.2022.04.016.

56. Morgan IGFrench ANAshby RSet alThe epidemics of myopia: Aetiology and preventionProg Retin Eye Res2018;62:13449DOI10.1016/j.preteyeres.2017.09.004.

57. Tan NMLiu JWong DKet alAutomatic detection of pathological myopia using variational level setAnnu Int Conf IEEE Eng Med Biol Soc2009;2009:360912DOI10.1109/IEMBS.2009.5333517.

58. Zhang ZXu YLiu Jet alAutomatic diagnosis of pathological myopia from heterogeneous biomedical dataPLoS ONE2013;8:e65736DOI10.1371/journal.pone.0065736.

59. Hemelings RElen BBlaschko MBet alPathological myopia classification with simultaneous lesion segmentation using deep learningComput Methods Programs Biomed2021;199:105920DOI10.1016/j.cmpb.2020.105920.

60. Du RXie SFang Yet alDeep learning approach for automated detection of myopic maculopathy and pathologic myopia in fundus imagesOphthalmol Retina2021;5:123544DOI10.1016/j.oret.2021.02.006.

61. Tan T-EAnees AChen Cet alRetinal photograph-based deep learning algorithms for myopia and a blockchain platform to facilitate artificial intelligence medical research: A retrospective multicohort studyLancet Digit Health2021;3:e31729DOI10.1016/S2589-7500(21)00055-8.

62. Li YFeng WZhao Xet alDevelopment and validation of a deep learning system to screen vision-threatening conditions in high myopia using optical coherence tomography imagesBr J Ophthalmol2022;106:6339DOI10.1136/bjophthalmol-2020-317825.

63. Sogawa TTabuchi HNagasato Det alAccuracy of a deep convolutional neural network in the detection of myopic macular diseases using swept-source optical coherence tomographyPLoS One2020;15:e0227240DOI10.1371/journal.pone.0227240.

64. Li YFoo L-LWong CWet alPathologic myopia: Advances in imaging and the potential role of artificial intelligenceBr J Ophthalmol2023;107:6006DOI10.1136/bjophthalmol-2021-320926.

65. Foo LLAng MWong CWet alIs artificial intelligence a solution to the myopia pandemic? Br J Ophthalmol2021;105:7414DOI10.1136/bjophthalmol-2021-319129.

66. Lin HLong EDing Xet alPrediction of myopia development among Chinese school-aged children using refraction data from electronic medical records: A retrospective, multicentre machine learning studyPLoS Med2018;15:e1002674DOI10.1371/journal.pmed.1002674.

67. Yang XChen GQian Yet alPrediction of myopia in adolescents through machine learning methodsInt J Environ Res Public Health2020;17:463DOI10.3390/ijerph17020463.

68. Yoo TKRyu IHChoi Het alExplainable machine learning approach as a tool to understand factors used to select the refractive surgery technique on the expert levelTransl Vis Sci Technol2020;9:8DOI10.1167/tvst.9.2.8.

69. Cui TWang YJi Set alApplying machine learning techniques in nomogram prediction and analysis for SMILE treatmentAm J Ophthalmol2020;210:717DOI10.1016/j.ajo.2019.10.015.

70. Rampat RDeshmukh RChen Xet alArtificial intelligence in cornea, refractive surgery, and cataract: Basic principles, clinical applications, and future directionsAsia Pac J Ophthalmol (Phila)2021;10:26881DOI10.1097/APO.0000000000000394.

71. Kane JXVan Heerden AAtik APetsoglou CAccuracy of 3 new methods for intraocular lens power selectionJ Cataract Refract Surg2017;43:3339DOI10.1016/j.jcrs.2016.12.021.

72. Chen QYu W-HLin Set alArtificial intelligence can assist with diagnosing retinal vein occlusionInt J Ophthalmol2021;14:1895902DOI10.18240/ijo.2021.12.13.

73. Ren XFeng WRan Ret alArtificial intelligence to distinguish retinal vein occlusion patients using color fundus photographsEye (Lond)2022DOI10.1038/s41433-022-02239-4.

74. Arrigo ACalamuneri AAragona Eet alStructural OCT parameters associated with treatment response and macular neovascularization onset in central serous chorioretinopathyOphthalmol Ther2021;10:28998DOI10.1007/s40123-021-00336-3.

75. Pfau Mvan Dijk EHCvan Rijssen TJet alEstimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligenceSci Rep2021;11:20446DOI10.1038/s41598-021-99977-4.

76. Xu FWan CZhao Let alPredicting post-therapeutic visual acuity and OCT images in patients with central serous chorioretinopathy by artificial intelligenceFront Bioeng Biotechnol2021;9:649221DOI10.3389/fbioe.2021.649221.

77. Ko JHan JYoon Jet alAssessing central serous chorioretinopathy with deep learning and multiple optical coherence tomography imagesSci Rep2022;12:1831DOI10.1038/s41598-022-05051-y.

78. Arrigo ACalamuneri ABordato Aet alVitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatmentSci Rep2020;10:17583DOI10.1038/s41598-020-74472-4.

79. Shao ELiu CWang Let alArtificial intelligence-based detection of epimacular membrane from color fundus photographsSci Rep2021;11:19291DOI10.1038/s41598-021-98510-x.

80. Camino AWang ZWang Jet alDeep learning for the segmentation of preserved photoreceptors on en Face optical coherence tomography in two inherited retinal diseasesBiomed Opt Express2018;9:3092105DOI10.1364/BOE.9.003092.

81. Fujinami-Yokokawa YPontikos NYang Let alPrediction of causative genes in inherited retinal disorders from spectral-domain optical coherence tomography utilizing deep learning techniquesJ Ophthalmol2019;2019:1691064DOI10.1155/2019/1691064.

82. Chen T-CLim WSWang VYet alArtificial intelligence-assisted early detection of retinitis pigmentosa the most common inherited retinal degenerationJ Digit Imaging2021;34:94858DOI10.1007/s10278-021-00479-6.

83. Wang ZCamino AHagag AMet alAutomated detection of preserved photoreceptor on optical coherence tomography in choroideremia based on machine learningJ Biophotonics2018;11:e201700313DOI10.1002/jbio.201700313.

84. Charng JXiao DMehdizadeh Met alDeep learning segmentation of hyperautofluorescent fleck lesions in Stargardt diseaseSci Rep2020;10:16491DOI10.1038/s41598-020-73339-y.

85. Miere ACapuano VKessler Aet alDeep learning-based classification of retinal atrophy using fundus autofluorescence imagingComput Biol Med2021;130:104198DOI10.1016/j.compbiomed.2020.104198.

86. Shah MRoomans Ledo ARittscher JAutomated classification of normal and stargardt disease optical coherence tomography images using deep learningActa Ophthalmol2020;98:e71521DOI10.1111/aos.14353.

87. Solebo ALTeoh LRahi JEpidemiology of blindness in childrenArch Dis Child2017;102:8537DOI10.1136/archdischild-2016-310532.

88. Reid JEEaton EArtificial intelligence for pediatric ophthalmologyCurr Opin Ophthalmol2019;30:33746DOI10.1097/ICU.0000000000000593.

89. Scruggs BAChan RVPKalpathy-Cramer Jet alArtificial intelligence in retinopathy of prematurity diagnosisTransl Vis Sci Technol2020;9:5DOI10.1167/tvst.9.2.5.

90. Mulay SRam KSivaprakasam Met alEarly detection of retinopathy of prematurity stage using deep learning approachComputer-Aided Diagnosis2019San Diego, United States DOI10.1117/12.2512719.

91. Brown JMCampbell JPBeers Aet alAutomated diagnosis of plus disease in retinopathy of prematurity using deep convolutional neural networksJAMA Ophthalmol2018;136:80310DOI10.1001/jamaophthalmol.2018.1934.

92. Redd TKCampbell JPBrown JMet alEvaluation of a deep learning image assessment system for detecting severe retinopathy of prematurityBr J Ophthalmol2018;103:5804DOI10.1136/bjophthalmol-2018-313156.

93. Taylor SBrown JMGupta Ket alMonitoring disease progression with a quantitative severity scale for retinopathy of prematurity using deep learningJAMA Ophthalmol2019;137:10228DOI10.1001/jamaophthalmol.2019.2433.

94. Campbell JPChiang MFChen JSet alArtificial intelligence for retinopathy of prematurity: Validation of a vascular severity scale against international expert diagnosisOphthalmology2022;129:e6976DOI10.1016/j.ophtha.2022.02.008.

95. Abdullah YISchuman JSShabsigh Ret alEthics of artificial intelligence in medicine and ophthalmologyAsia Pac J Ophthalmol (Phila)2021;10:28998DOI10.1097/APO.0000000000000397.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72